CD19 CAR-T agents to boost blood cancer market
European Pharmaceutical Review
FEBRUARY 8, 2023
Breyanzi will exhibit the largest compound annual growth rate (CAGR) at 30 percent, compared to Yescarta’s CAGR of 9 percent. Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively. billion in 2031.
Let's personalize your content